Adding mycophenolate after stem cell transplant for scleroderma
Treatments studied
Part of Skin clinical trials.
This trial is testing whether adding the drug mycophenolate after your stem cell transplant can improve the treatment of systemic sclerosis (scleroderma). It may help people who are already undergoing this transplant to have better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must be planning to have or be starting a stem cell transplant (AHSCT) for your scleroderma at The Ottawa Hospital
- Your kidney function must be adequate (not severely reduced)
- Your white blood cell and platelet counts must be within acceptable levels
- You must not have had a previous bad reaction to mycophenolate or related drugs
- If you are of childbearing age, you must agree to use highly effective birth control and cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether stem cells from umbilical cord blood can help treat systemic sclerosis (scleroderma). The goal is to see if this treatment can improve skin thickening and overall symptoms for people who haven't had success with standard therapies.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
This early-phase study tests whether umbilical cord-derived “cord blood–type” cells can reduce or improve severe systemic sclerosis (a type of hardening/scarring disease of connective tissue). It may help people whose current standard treatments haven’t worked or caused side effects.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.